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Poly(D,L-lactic-co-hydroxymethyl glycolic acid) (PLHMGA) is a 
biodegradable copolymer with potential as a novel carrier in polymeric 
drug delivery systems. In this study, the biocompatibility of PLHMGA 
microspheres (PLHMGA-ms) was investigated both in vitro in three 
different cell types (PK-84, HK-2 and PTECs) and in vivo at two 
implantation sites (by subcutaneous and subcapsular renal injection) 
in rats. Both monodisperse (narrow size distribution) and polydisperse 
PLHMGA-ms were prepared with volume weight mean diameter of 34 and 
17 µm, respectively. Mono and polydisperse PLHMGA-ms showed good 
cytocompatibility properties upon 72 hour incubation with the cells (100 
µg microspheres/600 µL/cell line). A mild foreign body reaction was seen 
shortly after subcutaneous injection (20 mg per pocket) of both mono and 
polydisperse PLHMGA-ms with the presence of mainly macrophages, few 
foreign body giant cells and myofibroblasts. This transient inflammatory 
reaction diminished within 28 days after injection, the time-point at which 
the microspheres were degraded. The degradation profile is comparable to 
the in vitro degradation time of the microspheres (i.e. within 35 days) when 
incubated at 37°C in phosphate buffered saline. Subcapsular renal injection 
of monodisperse PLHMGA-ms (10 mg) in rats was characterized with 
similar inflammatory patterns compared to the subcutaneous injection. 
No cortical damage was observed in the injected kidneys. In conclusion, 
this study demonstrates that PLHMGA-ms are well tolerated after in vivo 
injection in rats. This makes them a good candidate for controlled delivery 





Biocompatibility of PLHMGA microspheres
Introduction
Poly(D,L-lactic-co-glycolic acid) (PLGA) is a biodegradable aliphatic 
polyester that has been investigated for controlled delivery of low molecular 
weight drugs (Kim, et al. 2011), peptides (Shmueli, et al. 2013; Xuan, 
et al. 2013), proteins (Menon, et al. 2014; Reguera-Nuñez, et al. 2014; 
Wink, et al. 2014) and vaccine antigens (Huang, et al. 2014; Joshi, et 
al. 2013). PLGA is degraded by hydrolytic cleavage of ester bonds that 
connect the monomer units, and the final degradation products are lactic 
and glycolic acid, both endogenous compounds (Spenlehauer, et al. 1989; 
Vert, et al. 1994). An important drawback of PLGA matrices, however, is 
the formation of acidic degradation products which are detrimental for 
the stability and integrity of entrapped (therapeutic) proteins (Estey, et 
al. 2006; Park, et al. 1995). Denaturation of the formulated protein or 
structural modifications due to acid-catalyzed reactions will affect both 
therapeutic efficacy and can cause potential immunological responses to 
the formulated protein (Hermeling, et al. 2004; Patten and Schellekens 
2003). 
A novel copolymer, poly(D,L-lactic-co-hydroxymethyl glycolic acid) 
(PLHMGA) (Leemhuis, et al. 2006) has a similar molecular structure as 
PLGA with additional pendant hydroxyl groups on the polymer backbone 
(Figure 1). The degradation of this co-polymer and the release of entrapped 
proteins can be tailored by its copolymer composition (Ghassemi, et 
al. 2010; Leemhuis, et al. 2007; Samadi, et al. 2013b). Furthermore, 
PLHMGA based microspheres are peptide and protein friendly (Ghassemi, 
et al. 2010; Ghassemi, et al. 2012; Samadi, et al. 2013b). Owing to the 
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more hydrophilic nature of PLHMGA compared to PLGA, it has been 
demonstrated that the water-soluble acidic degradation products of 
PLHMGA are rapidly released from degrading microspheres into the 
external medium (Liu, et al. 2012). As PLHMGA is intended for use of 
delivering drugs in vivo, characterization of the in vivo biodegradation as 
well as biocompatibility properties of these copolymeric microspheres is 
required. 
The aim of this study is to evaluate the in vitro cytotoxicity and in vivo 
biocompatibility of PLHMGA microspheres (PLHMGA-ms). These 
tests are mandatory according to the International Organization for 
Standardization (ISO) guidelines for biological evaluation of implantable 
medical devices (ISO Guidelines April 23, 2013). PLHMGA-ms were 
prepared with two different methods, a conventional single emulsion 
solvent evaporation method for preparation of polydisperse microspheres 
and by membrane emulsification method for generating uniform size 
SnOct2 
BD Pd/C 








Figure 1. Synthesis of poly(lactic-co-hydroxymethyl glycolic acid) (PLHMGA) from D,L-Lactide and 3S-
(benzyloxymethyl)–6S–methyl–1,4–dioxane-2,5–dione (BMMG) by melt copolymerization with SnOct2 as 
catalyst and 1,4-butanediol (BD) as initiator. The protective benzyl groups were removed by 
hydrogenation using palladium on activated carbon (Pd/C) as a catalyst.  
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and 3S-(benzyloxymethyl)–6S–methyl–1,4–dioxane-2,5–dione (BMMG) by melt copolymeriza-
tion with SnOct2 as catalyst and 1,4-butanediol (BD) as initiator. The protective benzyl groups 
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microspheres. Previously, we have shown that microspheres prepared by 
this method of emulsification have high batch-to-batch reproducibility in 
terms of particle characteristics and release kinetics (Kazazi-Hyseni, et al. 
2014). Moreover, due to the uniform size, monodisperse microspheres also 
have better injectability and hence allows the use of smaller needles for 
the administration of microsphere suspensions. This is of special attention 
in the present study, in which we investigated the feasibility of injecting 
PLHMGA microspheres under the renal capsule. Subcapsular renal 
injection is a relatively new method for local delivery of therapeutics to the 
kidneys which was earlier tested for the injection of hydrogels (Dankers, 
et al. 2012). We created a small pocket between the capsule and the soft 
cortex tissue with a small blunt needle and used the same needle to inject a 
concentrated dispersion of the microspheres, to study their biocompatibil-
ity at this injection site. In addition, we studied the biocompatibility of 
PLHMGA microspheres after subcutaneous injection. 
The in vitro cytocompatibility was assessed in three different cell types, 
namely dermal fibroblasts (PK-84), proximal tubular epithelial cells (HK-2) 
and primary tubular epithelial cells (PTECs). For the in vivo biocompatibil-
ity assessment, both monodisperse and polydisperse PLHMGA-ms were 
injected subcutaneously in rats. The inflammatory response was studied 
along with the influence of particle size and polydispersity on the foreign 
body reaction. Furthermore, the degradation profile of PLHMGA-ms was 




Materials and Methods 
Materials
O-Benzyl-L-serine was purchased from Senn Chemicals AG (Dielsdorf, 
Switzerland). Tin (II) 2-ethylhexanoate (SnOct2), poly(vinyl alcohol) 
(PVA; Mw= 13,000-23,000 g/mol), palladium 10 wt% (dry basis) on 
activated carbon, hematoxylin solution and dimethylsulfoxide (DMSO) 
were obtained from Sigma-Aldrich (Germany). 1,4-Butanediol, 99+% 
was obtained from Acros Organics (Belgium). Carboxymethylcellulose 
(CMC, with viscosity of 2,000 mPa.s of a 1% solution in water) was 
obtained from Bufa B.V. (255611, The Netherlands). Sodium phosphate 
dibasic (Na2HPO4) and sodium azide (NaN3) were purchased from Fluka 
(The Netherlands). Dichloromethane (DCM) and tetrahydrofurane were 
purchased from Biosolve BV (The Netherlands). Sodium dihydrogen 
phosphate (NaH2PO4), sodium hydroxide (NaOH) and sodium chloride 
(NaCl) were supplied from Merck (Germany). Mouse anti rat CD68 
monoclonal antibody (clone ED-1) was obtained from AbD Serotec 
(MCA341R, Germany). Monoclonal mouse anti-human Actin (α-SMA) 
was obtained from Dako (Clone 1A4, Denmark). 
Polymer synthesis and characterization
Poly(D,L-lactic-co-hydroxymethyl glycolic acid) (PLHMGA) was 
synthesized as previously described (Leemhuis, et al. 2006), using 
butanediol as an initiator, to obtain a hydroxyl terminated co-polymer. 
In brief, BMMG (3S-(benzyloxymethyl)-6S-methyl-1,4-dioxane-
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al. 2006). In the second step BMMG (35 mol%) and D,L-lactide (65 
mol%) were copolymerized in the melt at 130°C using butanediol and 
tin (II) 2-ethylhexanoate as initiator and catalyst, respectively, to yield 
poly(D,L-lactic-ran-benzyloxymethyl glycolic acid) (PLBMGA). Next, 
the resulting PLBMGA was dissolved in chloroform and subsequently 
precipitated in cold methanol, and dried in vacuo. In the third step, the 
protective benzyl groups of PLBMGA were removed by hydrogenation of 
the polymer dissolved in tetrahydrofuran, using 10% w/w palladium on 
activated carbon (Pd/C) as a catalyst, for 16 hours at room temperature. 
The catalyst was removed by filtration through 0.2 μm nylon filters 
(Alltech Associates) and the formed copolymer, PLHMGA, was dried in 
vacuo (Figure 1).  
The molecular weight of the polymer was determined by GPC (Waters 
Alliance System) with a Waters 2695 separating module and a Waters 
2414 refractive index detector, using tetrahydrofuran as solvent at a flow 
rate of 1 mL/min; polystyrene standards (PS-2, Mw = 580 – 377,400 Da, 
EasiCal, Varian) were used for calibration. Two PL-gel 5 μm Mixed-D 
columns fitted with a guard column (Polymer Labs, Mw range 0.2 – 400 
kDa) were used. The composition of the copolymer was determined by 
NMR (Gemini-300 MHz) in chloroform-d, 99.8 atom% (Sigma-Aldrich) 
as a solvent (Leemhuis, et al. 2006). 
PLHMGA- 1H NMR (CDCl3): δ = 1.4-1.6 (m, 3H, -CH3), 3.8-4.1 
(m, 2H, -CH2-OH), 5.0-5.3 (m, 2H, -CH-CH2-OH and –CH-CH3)
64
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The thermal properties of the copolymer were measured with differential 
scanning calorimetry (DSC - Q 2000, TA Instruments). Approximately 
5 mg of copolymer was transferred into an aluminum pan (T zero pan/
lid set, TA Instruments) and the sample was scanned with a modulated 
heating method in three cycles (Ghassemi, et al. 2010). The sample was 
heated until 120ºC (5ºC/min) and then cooled down to – 50ºC, followed 
by a heating until 120ºC (5ºC/min). The temperature modulation was 
±1ºC/min. The glass transition temperature (Tg) was determined from 
the second heating scan. Residual palladium in PLHMGA, used as a 
catalyst during the de-protection step, was measured with instrumental 
neutron activation analysis (Technical University of Delft). Around 100 
mg of PLHMGA was packed in high purity polyethylene capsules and 
was irradiated at a neutron flux of 4.5 x1016 m-2 s-1. The γ ray spectra were 
acquired using various independently calibrated detectors. The spectra 
obtained were interpreted using the nuclear data set (Blaauw 1995). The 
detection limit of palladium with this method is 2.4 ppm.  
Preparation of polydisperse and monodisperse PLHMGA-ms 
Monodisperse PLHMGA-ms were prepared using a membrane 
emulsification method with a single emulsion (O/W) as described in detail 
elsewhere (Kazazi-Hyseni, et al. 2014; Nakashima, et al. 2000). The particles 
were prepared aseptically in a flow cabinet using autoclaved equipment 
and sterile water. The oil phase (O) contained 3 g of polymer dissolved in 
20.3 mL DCM (10%; w/w). This solution was then pushed through the 
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rate of 12 mL/h by using a syringe pump (Nexus 6000, Chemyx, USA) into 
the continuous phase (W) containing 400 mL of 4% PVA (the ratio of the 
oil phase and the continuous phase was 1:20). Polydisperse PLHMGA-ms 
were prepared with conventional single emulsion (O/W) method. Two 
grams of polymer were dissolved in 13.5 mL DCM (10%; w/w) and 67.5 
ml of 0.5% PVA solution was added. The mixture was homogenized with 
Ultra-Turrax T8 (Ika Works, USA) with dispersing element S10N-10G, at 
a speed of 20,000 rpm for 30 seconds, and then added dropwise to 270 mL 
of 4% PVA solution. For both methods, the collected droplets were stirred 
for three hours at room temperature to evaporate DCM. The hardened 
microspheres were washed three times with water by centrifuging at 3000 
rpm for 2 minutes (Rotina 380, Hettich, Germany) and subsequently 
collected after freeze-drying (Alpha 1-2, Martin Christ, Germany). Single 
batches were used for in vitro cytocompatibility and in vivo biocompatibil-
ity testing.
Characterization of PLHMGA-ms
 The size of the particles was measured with an optical particle sizer 
(Accusizer 780, California, USA). At least 5000 microspheres were 
analyzed and the volume-weight mean particle diameter is reported as 
the mean particle size. The morphology of the microspheres was analyzed 
with scanning electron microscope (SEM, Phenom, FEI Company, The 
Netherlands). Lyophilized microspheres were transferred onto 12-mm 
diameter aluminum specimen stubs (Agar Scientific Ltd., England) using 
double-sided adhesive tape. Prior to analysis, the microspheres were coated 
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with platinum using an ion coater under vacuum. The residual amount of 
DCM in the microspheres was measured with NMR (Varian Gemini-300) 
with DMSO-d6 as a solvent (Avdovich, et al. 1991; Jones, et al. 2005). 
Samples of 50 mg were dissolved in 1 mL of DMSO for one hour and spiked 
with 5 mg of 1,4-dinitrobenzene (OekanarR, Fluka) as the internal standard. 
The amount of the DCM was calculated from the NMR spectra according 
to the following equation, as adapted from Jones et al. (Jones, et al. 2005): 
where, Mw is the molecular weight and No.H is the number of protons 
of the peak (4H for 1,4-dinitrobenzene and 2H for DCM). The residual 
amount of DCM in the microspheres should be below the maximum 
concentration allowed by FDA, i.e. concentration limit of 600 ppm or 
the permitted daily exposure of 6 mg/day) (FDA Guidance Documents 
December, 1997; Grodowska and Parczewski 2010). 
Potential bacterial contamination of the microspheres was determined 
by inoculation of 5 mg of dry PLHMGA-ms (dispersed in sterile water) 
on blood agar plates. The plates were incubated at 37°C for 4 days and 
were checked daily for the presence of bacterial colonies. The endotoxin 
levels were determined using the Limulus assay (Toxicon Europe, Leuven, 
Belgium).
In vitro degradation studies
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7.4 (0.056 M NaCl, 0.033 M Na2HPO4, 0.066 M NaH2PO4 and 0.05 
% (w/w) NaN3) and incubated at 37°C while mildly shaking. A total of 
six vials was used. At predetermined time-points one vial was removed, 
centrifuged (4000 rpm, 5 min) and the pellet was washed three times with 
water and freeze-dried overnight. The microspheres were measured for dry 
weight and the molecular weight of the polymers was analyzed using GPC. 
In vitro cytotoxicity study
Cell culture
Monodisperse and polydisperse PLHMGA-ms were incubated  with 
three different cell types (human skin fibroblasts (PK-84), human proximal 
tubular cells (HK-2) and human primary tubular epithelial cells (PTECs)). 
The PK-84 were cultured in RPMI 1640 medium (Lonza, Breda, The 
Netherlands), supplemented with 10% v/v fetal calf serum (Perbio Science, 
Etten-Leur, The Netherlands) and with standard additives. The HK-2 and 
PTECs were cultured in 1:1 v/v Ham’s F12 (L-glutamine) and in Dulbecco’s 
modified Eagle’s medium supplemented with 1% v/v glutamine, 1% v/v 
penicillin, 0.01 mg/L epidermal growth factor, 10 mg/L insulin, 5.5 mg/L 
transferrin, 6.7 µg/L sodium selenite, 36 µg/L hydrocortisone and 2 mM 
glutamax. The medium of HK-2 was supplemented with 10% v/v fetal 
calf serum, whereas the medium of PTECs was supplemented with 1% 





For the preparation of the extracts of microspheres, 5 mg PLHMGA-ms 
was incubated for 24 hours at 37°C in 25 mL of complete culture 
medium. This method allows the extraction of both polar and nonpolar 
leachables from the microspheres (ISO Guidelines April 23, 2013). After 
24h-incubation, the samples were centrifuged at 300 g. In a similar 
way we prepared extracts of latex rubber (thickness 3-4 mm; Hilversum 
Rubber Factory, Hilversum, The Netherlands) and of polyurethane film 
(thickness about 1 mm; made from 2363-55D-pellethane® resin; Dow 
Chemical, Midland, MI, USA) that were used as a positive cytotoxic 
control (Latex) and as a negative non-cytotoxic control (polyurethane), 
respectively. PK-84, HK-2 and PTECs were seeded in 24-well plates (cell 
density of 15,000 cells/cm2) and after 24 h the medium of the cells was 
replaced with 500 µL of the extracts of PLHMGA-ms (corresponding to 
100 µg microspheres), latex and polyurethane. Cells were incubated for 
48 h followed by measurements with CyQuant cell proliferation assay (for 
quantification of nucleic acid content) and MTS assay (for mitochondrial 
activity measurements).
Direct contact assay
For direct contact assay, the microspheres were dispersed in complete 
medium (100 µg in 600 µL) and added to the cell cultures (cell density of 
15 000 cells/cm2). Small pieces of polyurethane film and latex rubber were 
used as a negative and positive control to show the behavior of the cells in 
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Groot, et al. 2001). Cells were cultured for 72 h and the cell morphology 
was examined every day. The cell viability was analyzed with CyQuant cell 
proliferation assay and MTS assay.
Cell proliferation assay
The CyQuant® cell proliferation assay (Invitrogen, The Netherlands) 
was performed according to the manufacturer’s instructions. In brief, 
after removing the culture medium (including floating and dead cells) 
the cells were stored at -80°C for 48 h. Subsequently, culture plates were 
defrosted at room temperature and the CyQuant® green dye/cell-lysis 
buffer was added to each well. The green dye exhibits strong fluorescence 
enhancement when bound to cellular nucleic acids. After 5 min incubation 
at room temperature, the fluorescence was quantified using a fluorescence 
microplate reader (Varioscan, Thermo Fisher Scientific Inc.) with a 
480/520-nm filter set. 
Mitochondrial activity assay
The mitochondrial activity - MTS assay (CellTiter 96® AQueous One 
Solution, Promega Benelux Bv, The Netherlands) was performed according 
to manufacturer’s instructions. Briefly, 100 µL of the culture medium 
containing the samples was mixed with 20 µL of the MTS reagent. The 
MTS reagent is reduced by metabolically active cells into a colored product. 
After 2 hour incubation at 37°C and 5% CO2 atmosphere the absorbance 
was recorded at 490 nm with a fluorescence microplate reader (Varioscan, 





Animal experiments were carried out in 10-12 week old male Fischer 
344/NCrHsd rats (Harlan Nederland, The Netherlands; n=3/time-point). 
Animals were fed laboratory chow and acidified water ad libitum, and 
were housed according to institutional rules with 12:12 hours dark/light 
cycles. The protocol was approved by the Animal Ethical Committee of 
the University of Groningen. During the injections, rats were anesthetized 
under general isoflurane/O2 inhalation and palliative treatment was used 
consisting of buprenorphine. At specific time-points rats were sacrificed by 
cervical neck dislocation.
Subcutaneous injection
Mono and polydisperse PLHMGA-ms suspensions were prepared by 
mixing 20 mg of the microspheres with 150 µl of an autoclaved viscous 
carrier (0.4% carboxymethylcellulose-CMC, 0.02% Tween-20 and 5% 
mannitol in water). Microparticle suspensions were injected subcutaneous-
ly on the back of the rats. Injection sites were explanted at day 7, 14 and 
28. Implants were fixed in zinc fixative solution (0.1M Tris-buffer, 3.2 mM 
calcium acetate, 23 mM zinc acetate, 37 mM zinc chloride, pH 6.5-7; 
Merck, Darmstadt, Germany) overnight, prior to paraffin embedding. 
Implants were cut into 4 µm thick sections.  
Subcapsular renal injection
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were used. A midline incision was made under the left kidney capsule 
of a rat and 50 μl of microsphere suspension (10 mg of microspheres in 
50 µL of 0.4% CMC, 0.02% Tween-20 and 5% mannitol in water) was 
injected with a 26G blunt Hamilton needle (Chrom8 International, the 
Netherlands). The kidneys were explanted at day 3, 7 and 14. Kidneys 
were flushed in vivo with saline solution, excised and paraffin-embedded. 
Implants were cut into 4 µm thick sections.
(Immuno)histochemistry
Tissue sections were stained for infiltration of macrophages (ED-1 
macrophage marker) and for myofibroblasts (α-SMA staining). Four µm 
thick sections were deparaffinized and antigen retrieval was performed 
overnight in a 0.1M Tris-HCl buffer, pH 9.0, at 80°C (Koopal, et al. 1998). 
The non-specific binding was blocked with 2% bovine serum albumin 
for 30 min, while the endogenous peroxidase activity was suppressed by 
incubating the samples in 0.1% H2O2 for 10 min. In ED-1 staining, sections 
were then incubated with mouse-anti-rat ED-1 monoclonal antibody (10 
µg/mL) for 1h followed by horseradish peroxidase-conjugated rabbit-anti-
mouse polyclonal antibody (13 µg/mL; DAKO, Denmark) for 30 min. For 
α-SMA staining, after antigen retrieval and blocking of the non-specific 
binding, tissue sections were incubated in mouse α-SMA monoclonal 
antibody (0.44 µg/mL) for 1h, followed by incubation in horseradish-
conjugated rabbit-anti mouse polyclonal antibody (13 µg/mL; DAKO, 
Denmark) for 30 min. After the incubation with the secondary antibody 
all sections were washed three times with PBS and the enzyme activity 
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was developed with 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich, The 
Netherlands). All tissue sections were counterstained with hematoxylin for 
5 minutes at 37°C. 
Results and discussion
Characteristics of the PLHMGA copolymer 
The synthesized PLHMGA (Figure 1) had an average molecular 
weight of 22 kDa (relative to the polystyrene standards) with a PDI of 
1.7 as measured by GPC. The copolymer composition was 34/66 mol/
mol (BMMG/D,L-lactide before hydrogenation) as measured with 
NMR (feed ratio 35/65). The glass transition temperature of PLHMGA 
(Tg) was 35.6°C. Due to the use of palladium-based catalyst during the 
de-protection step, the obtained copolymer might contain residual amounts 
of this metal. Instrumental neutron activation analysis showed that the 
palladium content in PLHMGA was 174 ppm, which corresponds to 
1.74 µg of palladium in 10 mg of PLHMGA-ms. According to European 
Medicines Agency, the parenteral permitted daily exposure to palladium 
is 10 µg/day (for a 50 kg person) while LD50 values for palladium salts 
range from 3-4900 mg/kg depending on the type of palladium salt and 
route of  administration (EMEA Guideline: Doc. Ref. EMEA/CHMP/
SWP/4446/2000). Based on these criteria, we do not expect adverse events 
in the animal studies due to the residual amounts of palladium catalyst.
Characteristics of the PLHMGA-ms 
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emulsification method. The obtained microspheres had a volume weight 
mean diameter of 34 µm and were quite monodisperse (distribution: 
30-38 µm) (Figure 2, A, C). Polydisperse PLHMGA-ms were prepared 
with a conventional single emulsion method and had a mean particle size 
of 17 µm (distribution: 5-46 µm) (Figure 2, B, D). Scanning electron 
microscopy (SEM) showed that the microspheres had smooth surface and 
no visible pores (Figure 2, A, B). The residual DCM content measured 
with NMR was <400 ppm for both microsphere batches which is below 
the maximum recommended amount by Food and Drug Administration 
(600 ppm or 6 mg/day) (FDA Guidance Documents December, 1997; 
Grodowska and Parczewski 2010). No bacterial contamination was 
detected in the prepared microsphere batches. The endotoxin level of the 
microsphere dispersions was within the approved FDA norm (0.5 EU/
mL). 
When incubated in PBS buffer at 37°C, both mono and polydisperse 
PLHMGA-ms showed 80 % weight loss within 35 days, with gradual 
decrease in the molecular weight (Figure 3). This is in agreement 
with previously published data of PLHMGA with similar copolymer 
composition and molecular weight (Ghassemi, et al. 2009). No apparent 
differences were seen in the degradation profile between mono and 
polydisperse microspheres, most probably due to the small differences of 
the average size of the microspheres (34 and 17 µm). According to another 
study, PLGA microspheres with an average diameter of 3 and 20 µm had 
similar degradation patterns, whereas nanoparticles of 300 nm in size 
degraded slower (Samadi, et al. 2013a).
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PLHMGA-ms are known to degrade by hydrolysis into lactic acid and 
hydroxymethyl glycolic acid (Leemhuis, et al. 2007; Samadi, et al. 2013b), 
both endogenous small molecular weight acidic compounds. The latter 
compound is a derivative of serine, which is converted into glyceric acid 
and further metabolized via the glycolytic pathway (Rabson, et al. 1962). 
Figure 2. Representative SEM photographs of PLHMGA-ms (A, B; magnification 1500x) and 
the results of the volume weight particle diameter as measured with AccuSizer (C, D). A and 
C: monodisperse PLHMGA-ms prepared with membrane emulsification method and B and D: 
polydisperse PLHMGA-ms prepared with a conventional solvent evaporation method.
In vitro cytocompatibility of PLHMGA-ms: extraction test and direct contact 
assay
The in vitro cytocompatibility of PLHMGA-ms was tested using three 
different cultured cell types, i.e. PK-84 (human skin fibroblasts), HK-2 
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tubular epithelial cells). These cell types also reflect the tissues in which the 
microspheres were evaluated for in vivo biocompatibility (PK-84 for the 
subcutaneous injection and HK-2 and PTECs for the subcapsular renal 
injection). Figure 4 shows the results from the cytocompatibility study 
of PLHMGA-ms incubated with PK-84 cells. PLHMGA-ms did not 




Figure 3. In vitro degradation of monodisperse (in blue closed squares) and polydisperse (in red open 
squares) PLHMGA-ms. Solid lines represent the residual weight (%), whereas the dashed lines represent 










































Figure 3. In vitro degradation of monodisper e (in blue closed squares) and po ydispe se (in red 
opensquares) PLHMGA-ms. Solid lines represent the residual weight (%), whereas the dashed lines 
represent the weight average molecular weight (Mw) over time.
assay and upon incubation with the 24 h-extracts of the microspheres. No 
significant differences were seen between polydisperse and monodisperse 
PLHMGA-ms in the cell viability assays. Proliferation of the cells was 
comparable to the control cultures and to polyurethane exposed cells, 
which served as a control material with good biocompatibility. As a positive 
(i.e. cytotoxic) control in our assays, we exposed the cells to latex rubber 
and latex rubber extracts. Extracts of small pieces of latex or direct contact 
with this material resulted in detachment of exposed cells from the culture 
plate and extensive cellular lysis was observed within the first 24h (Figure 
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4E; last panel). Similar cytocompatibility data were also obtained using 
HK-2 (Figure 5) and PTECs (Figure 6). Thus, PLHMGA-ms showed 
excellent cytocompatibility with the studied cells. These data encouraged 
further in vivo biocompatibility studies with this copolymer (described in 
the next sections). 
In vivo biocompatibility after subcutaneous injection of PLHMGA-ms
The in vivo biocompatibility of mono and polydisperse PLHMGA-ms 
was assessed after subcutaneous injection of 20 mg microspheres in 
Figure 4. In vitro cytocompatibility of PLHMGA-ms (5 mg/600 µL) upon incubation 
with human skin fibroblasts (PK-84). PK-84 were exposed to monodisperse and polydisperse 
PLHMGA-ms in the direct contact assay for 72 h (A and C) and to their 24-hour extracts for 48 
h (B and D). E: cell morphology in direct contact assay (magnifications 100x); arrows indicate the 
monodisperse PLHMGA-ms. Cell viability was assessed with MTS and cell proliferation assay. 
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rats. The tissue samples were explanted at days 7, 14 and 28 and tissue 
sections were stained with ED-1 and α-SMA (Figure 7). PLHMGA-ms 
were visible in the tissue sections as unstained white round spheres. In 
tissues injected with monodisperse PLHMGA-ms, a mild inflammatory 
reaction was observed at day 7 after injection with the recruitment of 
few inflammatory cells, from which the majority were ED-1 expressing 
macrophages (Figure 7, A) capable of phagocytosis (Dijkstra, et al. 1985). 
The presence of few foreign body giant cells (FBGCs) was also observed, 
which are formed by the fusion of macrophages in response to the foreign 
material (Anderson 2001). Few myofibroblasts in samples explanted at 
Figure 5. In vitro cytocompatibility of PLHMGA-ms (5 mg/600 µL) upon incubation with 
human proximal tubular cells (HK-2). HK-2 cells were exposed to monodisperse and polydisperse 
PLHMGA-ms in the direct contact assay for 72 h (A and C) and to their 24-hour extracts for 48 
h (B and D). E: cell morphology in direct contact assay (magnifications 100x); arrows indicate the 
monodisperse PLHMGA-ms. Cell viability was assessed with MTS and cell proliferation assay. 
Polyurethane and latex were used as a negative and a positive control, respectively.
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day 7 were detected with α-SMA staining (Figure 7, D). Myofibroblasts 
are cells with features of smooth muscle cells and are responsible for the 
wound contraction (Desmoulière, et al. 2003) and are also responsible 
for synthesizing collagen. Collagen forms the basis of the fibrous capsule, 
which plays a crucial role in the tissue repair and is considered a normal 
reaction feature towards the implanted foreign material (Anderson and 
Shive 1997; Anderson 2001). Staining for α-SMA also allows detection 
of blood vessels, since vascular smooth muscle cells express this marker 
(Skalli, et al. 1986). Scattered capillaries and arterioles were observed in 
Figure 6. In vitro cytocompatibility of PLHMGA-ms (5 mg/600 µL) upon incubation with 
human primary tubular epithelial cells (PTECs). PTECs were exposed to monodisperse and polydis-
perse PLHMGA-ms in the direct contact assay for 72 h (A and C) and to their 24-hour extracts for 
48 h (B and D). E: cell morphology in direct contact assay (magnifications 100x); arrows indicate 
the monodisperse PLHMGA-ms. Cell viability was assessed with MTS and cell proliferation assay. 
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sample tissues injected with monodisperse PLHMGA-ms and explanted 
at day 7. The presence of erythrocytes in the vessel lumina (Figure 
7, D) suggests functional blood vessels. The inflammatory reaction 
(macrophages, FBGCs) and myofibroblasts were also seen at day 14, when 
the microspheres fragmented into smaller residues < 10 µm (Figure 7, 
B, E). At day 28, no particle residues were detected and few infiltrating 
macrophages were still present (Figure 7, C). Myofibroblasts were virtually 
absent (Figure 7, F), marking the end of the fibrotic response towards 
monodisperse PLHMGA-ms. No fibrous capsule was detected, which 
indicates a relatively mild foreign body reaction (Shishatskaya, et al. 2008). 





















   
 
 
Figure 7. Histological pictures of subcutaneous tissues in which monodisperse PLHMGA-ms were 
injected. A-C: ED-1 staining (macrophages are stained in brown, blue arrow); D-F: α-SMA staining 
(myofibroblasts are stained in pink; red arrow), blood vessels are stained in red (black arrow). 








Figure 7. Histological pictures of subcutaneous tissues in which monodisperse PLHMGA-ms 
were injected. A-C: ED-1 staining (macrophages are stained in brown, blue arrow); D-F: α-SMA 
staining (myofibroblasts re stained in pink; red arrow), blood vessels are stained in red (black 
arrow). icrospheres (m) remain unstained in both stainings and are visible as white spheres at all 
time-points; (mag ification 40x).
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of 30 µm were investigated for their biocompatibility after subcutaneous 
injection in rats up to 4 weeks after their administration (Zandstra, et 
al. 2014). As expected from the type of PLGA used in this study, these 
microspheres hardly showed degradation during the time course of the 
study and only low numbers of infiltrated inflammatory cells were observed, 
in agreement with the mild foreign body reaction to PLGA. Polydisperse 
PLGA microspheres as well as other types of PLGA matrices have been 
studied extensively for their foreign body reaction and biocompatibility 
(Anderson and Shive 1997; Athanasiou, et al. 1996; Cadée, et al. 2001; 
Kohane, et al. 2002). Visscher et al. (Visscher, et al. 1985; Visscher, et 
al. 1987; Visscher, et al. 1988) reported studies of the biocompatibil-
ity of 30 µm diameter PLGA (50/50) microspheres after intramuscular 
injection in rats. The authors observed a mild inflammatory reaction for 
a period of nine weeks with the presence of lymphocytes, macrophages 
and FBGCs. Phagocytosis of particles was observed around day 42 after 
injection, the time-point when particles became smaller than 10 µm in size 
(Cadée, et al. 2001). Increased infiltration of macrophages was reported 
at day 56 (Visscher, et al. 1985). The end of the inflammatory response 
in tissues injected with PLGA microspheres was observed around day 
60 after administration (Visscher, et al. 1985). Prolonged inflammatory 
reaction of PLGA microspheres as compared to the 28 days observed for 
PLHMGA-ms is caused by the longer (two-month) degradation time of 























   
   
 
 
Figure 8. Histological pictures of subcutaneous tissues in which polydisperse PLHMGA-ms were injected. 
A-C: ED-1 staining (macrophages are stained in brown); D-F: α-SMA staining (myofibroblasts are stained 
in pink (red arrow), blood vessels are stained in red (black arrow). Microspheres (m) remain unstained in 







Figure 8. Histological pictures of cutaneou  tissues in which polydisperse PLHMGA-ms were 
injected. A-C: ED-1 staining (macrophages are stained in brown); D-F: α-SMA staining (myofibro-
blasts are stained in pink (red arro ), blood vessels are stained in red (black arrow). Microspheres 
(m) remain unstained in both stainings and are visible as white spheres; (magnification 40x).
The intensity of the inflammatory reaction towards injected polymeric 
microspheres is also dependent on particle size distribution. In this study, 
the effect of particle size distribution on the biocompatibility was tested 
by subcutaneous injection of polydisperse PLHMGA-ms in rats, prepared 
by conventional single emulsion method, with size distribution between 5 
and 46 µm in diameter (mean: 17 μm). Tissues were explanted at days 7, 
14 and 28 and stained with ED-1 and α-SMA (Figure 8). As was the case 
for monodisperse PLHMGA-ms, prepared by membrane emulsification, 
substantial numbers of macrophages were observed on 7, 14 and 28 days, 
as well as FBGCs on day 7 and 14 (Figure 8, A-C). In comparison with 
monodisperse microspheres, increased vascularization was observed in 
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tissue samples at day 14 (Figure 8, E). Only a very few myofibroblasts 
were observed at day 7 and 14 (Figure 8, D, E).  Interestingly, some 
large particles were still present at day 28 after injection (Figure 8, C, 
F). Although increased inflammatory responses towards smaller particles 
have been reported in previous studies (Cadée, et al. 2001; Champion, 
et al. 2008; Tabata and Ikada 1988; Thomasin, et al. 1996; Visscher, et 
al. 1988), in the current study no significant differences were observed in 
the inflammatory reaction between the tissues injected with monodisperse 
and polydisperse PLHMGA-ms. 
In vivo biocompatibility after subcapsular renal administration of monodis-
perse PLHMGM-ms 
The biocompatibility of monodisperse PLHMGA-ms was also tested 
after subcapsular renal injection, which is a novel strategy to for local 
drug delivery in the kidney. The injected amount of microspheres (10 
mg in 50 µL vehicle) was optimized as the highest concentration of the 
microspheres that could be delivered under the kidney capsule in view 
of the high viscosity of such dispersion and the injection via a small size 
needle of only 26G. After the injection, the kidneys were explanted at 
day 3, 7, and 14. The results of the tissue sections stained with ED-1 and 
hematoxylin are given in Figure 9. Similar to the subcutaneous injection, 
microspheres injected under the renal capsule were visible until day 14 
as small particulates. Macrophages again appeared as the most abundant 
inflammatory cells in the injected tissues. They localized only at the 
implantation site between the cortex and the renal capsule. Macrophages 
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significant reduction at day 14 after injection. The injected microspheres 
and the inflammation reaction were localized between the cortex and 
renal capsule with no penetration into the peritubular space (Figure 9). 
This result shows that polymeric microspheres can be injected under the 
renal capsule without cortical damage or damage to the capsule due to 
the injection method. The biocompatibility of a subcapsular depot was 
previously studied for supramolecular hydrogels in rats (Dankers, et al. 
2012).  Similar to our results, they showed that subcapsular injected 
biomaterials primarily resulted in a thickening of the renal capsule with 
only minimal responses in the renal cortex. From our data we conclude 
that monodisperse PLHMGA-ms injected under the kidney capsule have 
a good biocompatibility and can therefore be used for local delivery of 
therapeutic molecules in the kidney.
In vitro-in vivo degradation of PLHMGA-ms
In vitro studies in a PBS buffer showed that PLHMGA-ms undergo 
80% mass loss during 35 days as described in paragraph 3.2 and at day 
28, around 30% of the original mass was present. After subcutaneous 
and subcapsular renal injection of monodisperse PLHMGA-ms, particles 
were virtually absent in the tissue sections explanted at day 28 and 14, 
respectively. This indicates a slightly faster in vivo degradation compared 
to in vitro. Similar findings have been reported for PLGA microspheres 
(Jiang, et al. 2005). It has been demonstrated that PLGA particles inside 
macrophages degrade faster than particles in buffer likely due to the 










Figure 9. Foreign body reaction elicited by monodisperse PLHMGA-ms injected under the kidney 
capsule, stained with ED-1 and counterstained with hematoxylin. The area marked with red arrows 
represents the subcapsular space where the microspheres where injected. This area was analyzed for 
histological examinations and for possible inflammatory responses. Macrophages are stained with brown, 
nuclei in blue while microspheres remain unstained and are visible as white spheres. Magnification: 5x 




Figure 9. Foreign body reaction elicited by monodisperse PLHMGA-ms injected under the kidney 
capsule, stained with ED-1 and counterstained with matoxylin. Th  area m rk  with red arrows 
represents the subcapsular space where the microspheres where injected. This area was analyzed 
for histological examinations and for possible inflammatory responses. Macrophages are stained 
with brown, nuclei in blue while microspheres remain unstained and are visible as white spheres. 
Magnification: 5x (A-C) and 20x (D-F).
Conclusion
Monodisperse and polydisperse PLHMGA-ms showed good 
cytocompatibility after incubation with PK-84, HK-2 and PTECs cells 
and are biocompatible in vivo after subcutaneous administration. Therefore 
both monodisperse and polydisperse PLHMGA-ms are promising drug 
delivery systems for subcutaneous injection. In addition, monodisperse 
PLHMGA-ms injected under the kidney capsule induced only a very 
(Van Apeldoorn, et al. 2004; Walter, et al. 2001), which may also have 
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localized inflammatory reaction at the site of the depot, showing the 
feasibility of this type of microspheres for local drug delivery to the kidney. 
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